Mirova Biomarin Pharmaceutical Inc Transaction History

Mirova

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$80.93 - $108.63 $80 - $108	-1 Reduced 0.05%	1,846 $191,000
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $151,749 - $179,048	1,847 New	1,847 $156,000
Q2 2022 Aug 12, 2022	SELL	$71.48 - $86.85 $323,232 - $392,735	-4,522 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$74.28 - $92.69 $19,684 - $24,562	-265 Reduced 5.54%	4,522 $348,000
Q4 2021 Feb 14, 2022	BUY	$71.72 - $91.47 $343,323 - $437,866	4,787 New	4,787 $422,000

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Mirova, based on Form 13F filings with the SEC.

Stay updated on Mirova with notifications on news.